Category - Developments

Developments

Titan Pharma, Braeburn terminate Probuphine license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn agreed to terminate a December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Under the...

May 30, 2018

Developments

Ortho RTi receives European patent allowance

Ortho Regenerative Technologies (CSE:ORTH) received a notice of allowance from the European Patent Office for a patent entitled, “Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma...

May 23, 2018

Developments

Cara Therapeutics licenses KORSAUVA to Vifor Fresenius JV

Cara Therapeutics (NASDAQ:CARA) licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in...

May 23, 2018

Developments

Beta Bionics receives FDA go-ahead for home trials of AI-guided bionic pancreas

Closely-held Beta Bionics received FDA approval to begin home-use clinical studies of an autonomous bionic pancreas that employs artificial intelligence to vary hormone doses in adults and children with Type 1 diabetes...

May 22, 2018

Developments

Nabriva posts positive pivotal results in second CABP trial

Nabriva Therapeutics (NASDAQ:NBRV) reported positive top-line results from its LEAP 2 clinical trial, the second of two global, Phase 3 clinical trials of its antibiotic, lefamulin. LEAP 2 evaluated the safety and...

May 22, 2018

Developments

Tear Film Innovations closes Series B financing

Closely-held Tear Film Innovations completed an $8.5-million Series B preferred stock round led by Visionary Ventures Fund and Bluestem Capital. “This successful funding round completes the capitalization for our growth...

May 22, 2018

Developments

Profound Medical presents positive initial data from TACT pivotal trial

Profound Medical (TSXV:PRN; OTCQX:PRFMF) presented positive initial data from its TACT pivotal study with its TULSA-PRO ablation device at the American Urological Association (AUA) annual meeting in San Francisco. The...

May 21, 2018

Developments

Danish trial with CellAegis autoRIC device completes enrollment

Closely-held CellAegis announced completion of patient enrollment in a large investigator sponsored trial to further assess the efficacy of remote ischemic conditioning (RIC) using its autoRIC device to deliver the RIC...

May 19, 2018

Developments

Canopy Growth to acquire shares in R&D, animal units it doesn’t already own

Canopy Growth (TSX:WEED) has agreed to acquire the shares it doesn’t already own in Canopy Health Innovations (CHI) and CHI’s subsidiary, Canopy Animal Health, bringing its affiliated research arm fully into the...

May 15, 2018

Developments

Zymeworks, Daiichi Sankyo expand bispecific antibody collaboration

Zymeworks (NYSE, TSX:ZYME) and Daiichi Sankyo entered into a new license agreement, building on their 2016 cross-licensing and collaboration agreement. “With a successful track record and our first bispecific antibody...

May 15, 2018

Category - Developments

Subscribe